FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

247 letters match. Newest first.

  1. Antaria Pty. Ltd.

    FDA warned Antaria Pty. Ltd. about manufacturing quality failures in its active drug ingredient, including poor out-of-specification investigations and testing.

    High risk
  2. Betone S.A. de C.V.

    FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.

    High risk
  3. Deqing Jiarou Daily Chemical Co., Ltd.

    Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  4. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  5. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  6. Colgin, Inc.

    FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

    High risk
  7. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  8. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  9. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  10. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  11. Omeza LLC

    FDA warned Omeza LLC over mold, insects and animal waste in drug manufacturing areas and unapproved nonprescription drugs.

    High risk
  12. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  13. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  14. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  15. Cerci Kozmetik Ve Otel Ekipmanlari Pazarlama Ic Ve Dis Ticaret Limited Sirketi

    FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.

    High risk
  16. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  17. National Chemical Laboratories

    National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.

    High risk
  18. Elemental Herbs Inc. d/b/a ALL good

    Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.

    High risk
  19. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  20. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk
  21. Signature Biologics, LLC

    FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.

    High risk
  22. Kor-Chem, Inc.

    Kor-Chem, Inc. made OTC hand sanitizer drugs with manufacturing violations, including shared equipment with industrial chemicals and missing identity and microbial testing.

    High risk
  23. PureChemPros LLC

    FDA warns PureChemPros over manufacturing quality failures and unapproved, misbranded hand sanitizer and hydrogen peroxide drugs.

    High risk
  24. Cosmobeauti Laboratories & Manufacturing Inc.

    FDA warns Cosmobeauti Laboratories over manufacturing rule violations for OTC sunscreen drugs, including backdated batch records and missing microbial testing.

    High risk
  25. Centaur Pharmaceuticals Private Ltd.

    FDA says Centaur Pharmaceuticals drugs were adulterated due to inadequate cleaning and cross-contamination.

    High risk
  26. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  27. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  28. LXR Biotech, LLC

    FDA says LXR Biotech, a contract maker of an OTC drug, shipped batches without testing components or finished product.

    High risk
  29. Stratus Biosystems, LLC dba CellGenuity Regenerative Science

    FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.

    High risk
  30. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  31. Row1 Inc. dba Regenative Labs

    FDA warned Regenative Labs that its umbilical cord products are unlicensed drugs, made under serious sterility and manufacturing failures.

    High risk
  32. Mr. Lulu LLC

    FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.

    High risk
  33. Pharmedica USA, LLC

    FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

    High risk
  34. Zermat International S.A. de C.V.

    FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.

    High risk
  35. Eco Lips, Inc.

    FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.

    High risk
  36. Omega Packaging Corp

    Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.

    High risk
  37. NuGeneration Technologies LLC

    FDA inspected NuGeneration Technologies' Emeryville, California drug plant and found CGMP failures in hand sanitizer release testing, ingredient and water testing, stability and process validation.

    High risk
  38. Dunagin Pharmaceuticals Inc. dba Massco Dental

    Dunagin Pharmaceuticals dba Massco Dental made oral drugs with CGMP violations including shared equipment and inadequate component testing.

    High risk
  39. Formology Lab Inc.

    FDA warned Formology Lab Inc. about manufacturing rule violations for drugs, including untested ingredients and unvalidated sunscreen processes.

    High risk
  40. Midlab Incorporated

    FDA cited Midlab in Athens, Tennessee for manufacturing violations and unapproved, misbranded hand sanitizer and antibacterial soap drugs.

    High risk
  41. Frenda Corporation

    FDA found Frenda made OTC alcohol and hand sanitizer under insanitary conditions with industrial chemical cross-contamination risk.

    High risk
  42. Profounda, Inc.

    FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

    High risk
  43. Gascó Industrial Corporation

    FDA cites Gascó Industrial for CGMP violations in OTC hand soap, antiseptics, and hand sanitizer, including shared equipment with industrial products.

    High risk
  44. Ultra Chem Labs Corporation

    FDA warns Ultra Chem Labs about methanol-tainted hand sanitizer sold as an unapproved, misbranded drug.

    High risk
  45. Delta Kozmetik Sanayi Ve Ticaret-Selim Yesil

    FDA warned Delta Kozmetik that its OTC drug products were adulterated due to CGMP violations.

    High risk
  46. Fei Fah Medical Manufacturing Pte. Ltd.

    FDA warned Fei Fah Medical Manufacturing over inadequate stability data, unvalidated test methods, and supplier testing failures for over-the-counter drugs.

    High risk
  47. Auto-Chlor System LLC

    Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.

    High risk
  48. Kari Gran Inc.

    Kari Gran Inc. released OTC SPF sunscreen drugs without adequate batch testing or stability data.

    High risk
  49. Invitrx Therapeutics, Inc.

    Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.

    High risk
  50. McConnell Labs Inc.

    McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.

    High risk